Highlights of the AAN Updated Guideline on Treating Motor Symptoms in Early Parkinson's Disease

2021 ◽  
Vol 21 (22) ◽  
pp. 13-16
Author(s):  
Stephanie Cajigal
2019 ◽  
Author(s):  
Isabel Cristina Echeverri ◽  
Maria de la Iglesia Vayá ◽  
Jose Molina Mateo ◽  
Francia Restrepo de Mejia ◽  
Belarmino Segura Giraldo

Context: Parkinson’s disease (PD) is catalogued as a disorder that causes motor symptoms; the evidence of literature shows the PD starts with non-motor signs, which can be detected in prodromal phases. These previous phases can be analyzed and studied through magnetic resonance images (MRI), electroencephalography (EEG) and microbiome.Objective: To systematically review the areas of the brain and brain-gut axis which affect in early Parkinson’s disease that can possibly be visualized and analyzed by MRI, EEG and the microbiome.Evidence acquisition: Pubmed and Embase databases were used until July 30, 2018 as to search for early Parkinson’s disease at its earliest non-motor symptoms stage by using MRI, EEG, and microbiome. The search was performed according to the requirements of a systematic review. In order to identify reports, we evaluated them following the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) criteria. Evidence synthesis: MRI and EEG have provided the advances to find features for PD over the last decade. Those techniques identify motor symptoms on substantia nigra where the patient shows a dopamine deficiency. However, over recent years, researchers have found that PD has prodromal phases, that is, PD is not simply a neurodegenerative disorder characterized by the dysfunction of dopaminergic. Thus, high field MRI, event-related potential (ERP) and microbiota data shows a significant change on the brain cortex, white and grey matter, the extrapyramidal system, brain signals and the gut.Conclusion: The structural MRI is a useful technique in detecting the stages of motor symptoms on the substantia nigra in patients with PD. The use of magnetic resonance as an early detector requires a high magnetic field, as to identify the areas which diagnose that the patient could be in the premotor stages. On the other hand, EEG performed well in detecting PD features. Furthermore, microbiome sequencing might include the classification of bacterial families that could help to detect PD in its prodromal phase. Thus, the combination of all these techniques can support the possibility of diagnosing PD in its very early stages.


2015 ◽  
Vol 86 (11) ◽  
pp. e4.80-e4
Author(s):  
Fahd Baig ◽  
Michael Lawton ◽  
Michal Rolinski ◽  
Claudio Ruffmann ◽  
Kannan Nithi ◽  
...  

ObjectiveTo delineate treatment and quality of life of non-motor symptoms (NMS) in early Parkinson's disease (PD) and first-degree relatives.BackgroundNon-motor symptoms (NMS) are an important prodromal feature of Parkinson's disease (PD). However, their frequency, treatment rates and impact on health-related quality of life (HRQoL) in the early motor phase is unclear.Methods769 population-ascertained PD subjects within 3.5 years of diagnosis and 287 control subjects were assessed. Validated severity questionnaires were employed to assess NMS symptoms across the following domains: (1) neuropsychiatric (2) gastrointestinal (3) sleep (4) sensory (5) autonomic (6) sexual. Health related quality of life (HRQoL), functional status and management were also evaluated.ResultsNMS were common in early PD. More than half of the PD cases had hyposmia, pain, fatigue, sleep disturbance or urinary dysfunction. PD cases had worse HRQoL scores than controls (OR 4.1, p<0.001) with depression, anxiety and pain being stronger drivers than MDS-UPDRS motor scores. Quality of life is affected in early PD, although 23% of participants reported no problems. NMS were rarely treated in routine clinical practice.ConclusionsDespite their major impact on HRQoL, NMS are usually under-recognised and treated. The use of screening tools could improve recognition and treatment of NMS in early PD.


2018 ◽  
Vol 26 (3) ◽  
pp. 400-406 ◽  
Author(s):  
X. Huang ◽  
S. Y.‐E. Ng ◽  
N. S.‐Y. Chia ◽  
F. Setiawan ◽  
K.‐Y. Tay ◽  
...  

2015 ◽  
Vol 22 (8) ◽  
pp. 1145-1150 ◽  
Author(s):  
P. Zis ◽  
P. Martinez-Martin ◽  
A. Sauerbier ◽  
A. Rizos ◽  
J. C. Sharma ◽  
...  

US Neurology ◽  
2009 ◽  
Vol 05 (01) ◽  
pp. 25
Author(s):  
Binit Shah ◽  
Tanya Simuni ◽  
◽  

Parkinson’s disease (PD) is the second most common neurodegenerative disease and affects more than one million people in the US. The management of PD involves treatment of motor and non-motor symptoms of the disease. The armamentarium of treatment options for PD has increased substantially over the last 10 years. This article reviews recent clinical trials investigating efficacy, complications of treatment, and possible neuroprotective agents in patients with early PD.


Sign in / Sign up

Export Citation Format

Share Document